To this end, targeting of CCR2+ macrophages using CCR2 inhibitors is an effective method of tumor control in mouse models of PDA and has shown safety and potential clinical activity in combination with FOLFIRINOX in patients (40, 56). The gene discussed is CCR2; the disease is Patent ductus arteriosus.